Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: Implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels

Psychiatry and Clinical Neurosciences

Volumn 60, Issue 3, 2006, Pages 389-393

  Yoshimura, Reiji ^a   Kaneko, Sachiko ^a   Shinkai, Koji ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

3 methoxy 4 hydroxyphenylglycol (MHPG); Brain derived neurotrophic factor (BDNF); Homovanillic acid (HVA); Obsessive compulsive disorder; Risperidone

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINE; CLOMIPRAMINE; FLUVOXAMINE; HALOPERIDOL; HOMOVANILLIC ACID; LITHIUM; RISPERIDONE; SEROTONIN TRANSPORTER; SULPIRIDE;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LOW DRUG DOSE; MALE; OBSESSIVE COMPULSIVE DISORDER; PLASMA; PREDICTION; SEROTONINERGIC SYSTEM; SERUM;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; HOMOVANILLIC ACID; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; OBSESSIVE-COMPULSIVE DISORDER; RISPERIDONE; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 33646694793     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2006.01519.x     Document Type: Article

References (26)

1. McDougle CJ Goodman WK Leckman JF The psychopharmacology of obsessive-compulsive disorder: implications for treatment and pathogenesis In Dunner DL (ed.). Psychiatric Clinics of North America Vol. 16 4th edn Saunders Philadelphia, PA 1993 749 766
2. Erzegovesi S Cavallini MC Cavadini P Diaferia G Locatelli Bellodi L Clinical predictors of drugs response in obsessive-compulsive disorder JClinPsychopharmacol 2001 21 272 275
3. McDougle CJ Price LH Goodman WK Charney DS Heninger GR A controlled clinical trial of lithium augmentation in fluvoxamine refractory obsessive-compulsive disorder: lack of efficacy JClinPsychopharmacol 1991 11 175 184
4. Pigott TA Pato MT L'Heureux F et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine treated patients with obsessive-compulsive disorder JClinPsychopharmacol 1991 11 242 248
5. Pigott TA L'Heureux F Hill JL Bihari K Bernstein SE Murphy DL A double blind study of adjuvant buspirone hydrochloride in clomipramine treated patients with obsessive-compulsive disorder JClinPsychopharmacol 1992 12 11 18
6. Mundo E Guglielmo E Bellodi L Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study IntClinPsychopharmacol 1998 13 219 224
7. McDougle CJ Goodman WK Leckman JF Lee NC Heninger GR Price LH Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics ArchGenPsychiatry 1994 51 302 308
8. McDougle CJ Goodman WK Price LH et al. Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder AmJPsychiatry 1990 147 652 654
9. McDougle CJ Fleishmann RL Epperson CN Wasylink S Leckman JF Price LH Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases JClinPsychiatry 1995 56 526 528
10. Erzegovesi S Guglielmo E Siliprandi F Bellodi L Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study EurNeuropsychopharmacol 2005 15 69 74
11. Kakihara S Yoshimura R Shinkai K et al. Prediction of response to risperidone treatment with respect to plasma concentrations of risperdone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6 IntClinPsychopharmacol 2005 20 71 78
12. van der Meersch-Mougeot V Diquet B Sensitive one-step extraction procedure for column liquid chromatographic determination of fluvoxamine in human and rat plasma JChromatgr 1991 567 441 449
13. Jacobsen FM Risperidone in the treatment of affective illness and obsessive-compulsive disorder JClinPsychiatry 1995 56 423 429
14. Stein DJ Bouwer C Hawkridge S Emsley RA Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder JClinPsychiatry 1997 58 119 122
15. McDougle CJ Epperson CN Pelton GH Wasylink S Price LH A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder ArchGenPsychiatry 2000 57 794 801
16. Benkelfat C Mefford IN Masters CF Nordahl TE King AC Cohen RM Plasma catecholamines and their metabolites in obsessive-compulsive disorder Psychiatry Res 1991 37 321 331
17. Thoren P Asberg M Bertilsson L Mellstrom B Sjoquvist F Traskman L Clomipramine treatment of obsessive-compulsive disorder 2: biochemical aspects ArchGenPsychiatry 1980 37 1289 1294
18. Swedo SE Leonard HL Kruesi MJ et al. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder ArchGenPsychiatry 1992 49 29 36
19. Denys D Zohar J Westenberg HG The role of dopamine in obsessive-compulsive disorder. Preclinical and clinical evidence JClinPsychiatry 2004 65 Suppl. 14 11 17
20. Yoshimura R Ueda N Nakamura J Low dosage of levomepromazine did not increase plasma concentrations of fluvoxamine IntClinPsychopharmacol 2000 15 233 235
21. DeVane CL Nemeroff CB An evaluation of risperdone drug interactions JClinPsychopharmacol 2001 21 408 416
22. Yasui-Furukori N Hidestrand M Spina E Facciola G Scordo MG Tybring G Different enantioselective 9-hydroxyrisperidone of risperidone by the two human CYP2D6 and CYP3A4 enzymes Drug MetabDispos 2001 29 1263 1268
23. Hollander E Simeon D Gorman JM Anxiety disorders In Hales RE Yudofsky SC Talbott JA (eds) Textbook of Psychiatry 3rd edn American Psychiatric Press Washington DC 1999 567 634
24. Karege F Perret G Bondolfi G Schwald M Bertschy G Aubry JM Decreased serum brain-derived neurotrophic factor levels in major depressed patients Psychiatry Res 2002 109 143 148
25. Shimizu E Hashimoto K Okamura N et al. Alternations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants BiolPsychiatry 2003 54 70 75
26. Sareen J Kirshner A Lander M Kjernisted KD Eleff MK Reiss JP Do antipsychotics ameliorate or exacerbate obsessive compulsive disorder symptoms? A systematic review JAffectDisord 2004 82 167 174